GlassScriptPhysician profile
Raymond R Rackley
NPI 1699719443
$151,645.78
in general payments reported to CMS, 2019-2025
25 companies · $37K in 2025
The $37K reported for 2025 was more than what 98% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $20K · 2021: $1,499 · 2022: $4,320 · 2023: $32K · 2024: $35K · 2025: $37K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $96K · Food and Beverage: $4,304 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,670 · Travel and Lodging: $912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $96,000.00 |
| Food and Beverage | $4,304.33 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,670.00 |
| Travel and Lodging | $912.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Checkpoint Surgical, INC | $136,311.36 | 2019-2025 | Checkpoint Stimulators |
| Medtronic, INC. | $9,261.10 | 2019-2025 | Interstim, Aps |
| Axonics, INC. | $1,821.94 | 2023-2024 | Axonics, Bulkamid |
| Medtronic USA, INC. | $1,202.13 | 2019-2020 | |
| Abbvie INC. | $733.55 | 2022-2025 | |
| Astellas Pharma US INC | $399.95 | 2019-2021 | |
| C. R. Bard, INC. & Subsidiaries | $388.15 | 2023-2025 | Bard Urinary Drainage Bag |
| Coloplast Corp | $303.76 | 2024-2025 | |
| Rochester Medical Corporation | $295.48 | 2019-2022 | |
| Urocure LLC | $182.40 | 2020-2023 | |
| Urovant Sciences INC | $132.50 | 2021 | |
| Blue Earth Diagnostics | $113.00 | 2023 | |
| Antares Pharma, INC. | $109.01 | 2022-2024 | Xyosted, Nocdurna, Tlando |
| Sumitomo Pharma America, INC. | $87.32 | 2023-2025 | Gemtesa |
| Boston Scientific Corporation | $65.75 | 2024-2025 | Advantage System, Moses 550 Dfl, Axonics |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $45.34 | 2025 | Endosheath Technology |
| Allergan, INC. | $41.28 | 2019-2020 | |
| 180 Medical, INC. | $33.48 | 2021-2022 | |
| Becton, Dickinson and Company | $25.97 | 2025 | Bard Urinary Drainage Bag |
| Janssen Biotech, INC. | $25.08 | 2025 | Erleada |
| Tolmar, INC. | $21.84 | 2025 | Eligard, Jatenzo |
| Halozyme INC | $18.67 | 2023 | |
| Urogen Pharma, INC. | $15.53 | 2025 | |
| Srs Medical Systems, INC. | $11.19 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3,800,417.80 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Rackley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.